On Tuesday, Blueprint Medicines Corp (NASDAQ: BPMC) was unchanged from the session before settling in for the closing price of $128.4. A 52-week range for BPMC has been $73.04 – $128.52.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 31.87% over the past five years. When this article was written, the company’s average yearly earnings per share was at 34.48%. With a float of $62.27 million, this company’s outstanding shares have now reached $64.56 million.
Let’s look at the performance matrix of the company that is accounted for 649 employees. In terms of profitability, gross margin is 95.84%, operating margin of -31.01%, and the pretax margin is -27.38%.
Blueprint Medicines Corp (BPMC) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Blueprint Medicines Corp stocks. The insider ownership of Blueprint Medicines Corp is 3.71%, while institutional ownership is 106.61%. The most recent insider transaction that took place on Jul 03 ’25, was worth 150,309. In this transaction CHIEF OPERATING OFFICER of this company sold 1,172 shares at a rate of $128.25, taking the stock ownership to the 63,546 shares. Before that another transaction happened on Jul 03 ’25, when Company’s CHIEF SCIENTIFIC OFFICER sold 1,051 for $128.25, making the entire transaction worth $134,791. This insider now owns 53,155 shares in total.
Blueprint Medicines Corp (BPMC) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 34.48% per share during the next fiscal year.
Blueprint Medicines Corp (NASDAQ: BPMC) Trading Performance Indicators
You can see what Blueprint Medicines Corp (BPMC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach 0.92 in one year’s time.
Technical Analysis of Blueprint Medicines Corp (BPMC)
Blueprint Medicines Corp (NASDAQ: BPMC) saw its 5-day average volume 2.23 million, a positive change from its year-to-date volume of 2.0 million. As of the previous 9 days, the stock’s Stochastic %D was 61.39%.
During the past 100 days, Blueprint Medicines Corp’s (BPMC) raw stochastic average was set at 99.32%, which indicates a significant increase from 51.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.27 in the past 14 days, which was lower than the 3.04 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $113.27, while its 200-day Moving Average is $98.05. Nevertheless, the first resistance level for the watch stands at $128.68 in the near term. At $128.97, the stock is likely to face the second major resistance level. The third major resistance level sits at $129.16. If the price goes on to break the first support level at $128.21, it is likely to go to the next support level at $128.02. Assuming the price breaks the second support level, the third support level stands at $127.73.
Blueprint Medicines Corp (NASDAQ: BPMC) Key Stats
There are 64,582K outstanding shares of the company, which has a market capitalization of 8.30 billion. As of now, sales total 508,820 K while income totals -67,090 K. Its latest quarter income was 149,410 K while its last quarter net income were 500 K.
